IDEAYA Biosciences (IDYA) Receivables - Net (2020 - 2026)

IDEAYA Biosciences (IDYA) reported Receivables - Net of $6.6 million for Q1 2026, up 9.83% sequentially from $6.0 million in Q4 2025.

IDEAYA Biosciences (IDYA) Receivables - Net (2020 - 2026) Analysis & Trends

IDEAYA Biosciences (IDYA) has 7 years of Receivables - Net data on file, last reported at $6.6 million in Q1 2026.

For the quarter ending Q1 2026, Receivables - Net changed N/A year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at $6.6 million (changed N/A YoY), and the FY2025 full-year result was $6.0 million, up 199000.0% from the prior year.
Receivables - Net grew to $6.6 million in Q1 2026, from $6.0 million in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $6.7 million in Q3 2023 to a low of $1000.0 in Q2 2024.
A 5-year average of $1.8 million and a median of $244000.0 in 2022 frame the typical range for Receivables - Net.
Across the five-year window, Receivables - Net slumped 99.7% in 2024 and surged 199000.0% in 2025, its largest moves.
Tracing IDYA's Receivables - Net over 5 years: stood at $200000.0 in 2022, then sank by 91.0% to $18000.0 in 2023, then sank by 83.33% to $3000.0 in 2024, then surged by 199000.0% to $6.0 million in 2025, then rose by 9.83% to $6.6 million in 2026.
Business Quant data shows IDYA's Receivables - Net at $6.6 million in Q1 2026, $6.0 million in Q4 2025, and $3000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	IDEAYA Biosciences	3.21 Bn	2.54 Bn	-

Download Data